How much should Lp(a) be lowered to translate into meaningful CV benefit?

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie M. Ballantyne, MD, FACP, FACC
0.25 credits
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program credits
- Julia Brandts, MD
0.75 program credits